Provider Statement
This activity is provided by Integrity CE, LLC.
Disclosure of Commerical Support
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.
Credits Available
- Physicians — maximum of 0.75 AMA PRA Category 1 Credit™
All other healthcare professionals completing this course will be issued a statement of participation
Target Audience
This educational activity has been designed to meet the needs of otolaryngic allergists, otolaryngologists, allergists, and specialty advanced practice clinicians involved in the management of chronic rhinosinusitis with nasal polyps (CRSwNP).
Program Overview
CRSwNP is a significant health burden, affecting about 25% to 30% of the 28.9 million US adults with chronic rhinosinusitis. These patients face increased risk of comorbidities, frequent need for functional endoscopic sinus surgery (FESS), and overreliance on oral corticosteroids (OCS). Moreover, many continue to have poor symptom control and impaired quality of life, often reporting poor sleep, depression, and social withdrawal despite standard care.
Join expert faculty in this interactive, case-based activity and work through real-world patient challenges, exploring key decision points. Along the way, faculty will provide guidance and insight on patient assessment, current evidence on the safety and efficacy of available treatments, strategies for individualized treatment selection, and approaches to overcoming barriers to optimal biologic use.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Implement both subjective and objective measures in the evaluation and assessment of patients with CRSwNP
- Select treatments for patients with CRSwNP based on individual patient characteristics and available evidence
- Implement strategies to overcome barriers to the optimal use of biologics in the treatment of patients with CRSwNP
Faculty
Christine Franzese, MD
Professor of Clinical Otolaryngology
Director of Allergy
Department of Otolaryngology – Head and Neck Surgery
University of Missouri
Columbia, Missouri
Michael Platt, MD, MSc
Associate Professor and Residency Director
Director of Rhinology and Endoscopic Skull Base Surgery
Department of Otolaryngology – Head and Neck Surgery
Chobanian and Avedesian School of Medicine
Boston University
Boston, Massachusetts
Accreditation Statement
Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Integrity CE, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflict of Interest
Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.
The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:
Christine Franzese, MD
Research Support: AstraZeneca, Eli Lilly, GlaxoSmithKline, Lyra, Regeneron, Sanofi, Upstream Bio
Speakers Bureaus: AstraZeneca, GlaxoSmithKline, Optinose, Regeneron, Sanofi
Michael Platt, MD, MSc
Consulting Fees: AstraZeneca, GI Reviewers, GlaxoSmithKline, Sanofi
The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this activity. During the period of November 7, 2025 through November 7, 2026, participants must:
- Read the learning objectives
- Complete the pretest
- Study the educational activity
- Complete the posttest and the evaluation form
A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.
Contact Information
For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or [email protected].